北京协和医院“小伙伴” 麻醉监护医疗器械小巨人今日上市丨打新早知道

Core Viewpoint - The company, Haiseng Medical, has successfully listed on the Beijing Stock Exchange, focusing on the research and manufacturing of anesthesia and monitoring medical consumables, establishing itself as a leading enterprise in this sector in China [1][3]. Company Overview - Haiseng Medical is recognized as a national-level specialized and innovative "little giant" enterprise, with a product matrix that includes anesthesia, monitoring, surgical, and nursing categories [1]. - The company has developed 14 core technologies that form a strong technical moat for its product matrix, including innovations in pressure sensors, signal acquisition, and various medical device manufacturing processes [6]. Financial Performance - The company reported significant revenue growth driven by its core technologies, with revenues from these products reaching 2.23 billion, 2.54 billion, 2.53 billion, and 1.32 billion from 2022 to the first half of 2025, accounting for over 83% of its main business income during these periods [6]. - The company has established stable relationships with major clients, achieving sales coverage across all 31 provinces, autonomous regions, and municipalities in China, as well as exporting to key international markets [6]. Market Position - Haiseng Medical is positioned as a leading enterprise in the anesthesia and monitoring medical consumables sector, with a competitive edge reflected in its product offerings and technological advancements [3][6]. - The company has a market capitalization of 1 billion yuan, with an issue price of 12.64 yuan per share [3]. Investment Direction - The company plans to allocate raised funds primarily towards upgrading and expanding production capacity for emergency medical devices (1.74 billion yuan, 46.95%), establishing a research and testing center (1.39 billion yuan, 37.52%), and building a marketing service base (0.58 billion yuan, 15.54%) [3]. Challenges - Haiseng Medical faces the risk of production capacity saturation, as its existing capacity is nearing full utilization. Without timely expansion, the company may struggle to meet the growing market demand, potentially hindering its future growth [7].

北京协和医院“小伙伴” 麻醉监护医疗器械小巨人今日上市丨打新早知道 - Reportify